We aimed to investigate uric acid and albumin ratio (UA/A) as a marker of short-term mortality in acute kidney injury (AKI). Both uric acid and albumin are strongly correlated with the development and mortality of AKI.
The patients hospitalized from May 2019 to September 2019 for AKI were included in this study. The diagnostic odds ratio (DOR), Youden index (J), and the area under a receiver operating characteristic curve (AUROC) determined a cut-off UA/A ratio for mortality. Cox-regression analysis was performed to identify UA/A as a prognostic marker of the 30-day mortality rate.
A total of 171 patients with an average age of 69.20±13.0 (45.6% women) were included in the study. The average UA/A ratio was 3.3±1.5 mg/g and 2.5±1.0 mg/g in the non-survivor and survivor groups, respectively (P=0.001). The best cut-off UA/A ratio associated with mortality was determined as 2.4 mg/g with a specificity of 52% and a sensitivity of 77% (DOR, 3.6; J, 28.8; AUROC, 0.644). Thirty-day cumulative survival rates of the low and high UA/A ratio groups were 85.9±4.0% and 63.7±5.0%, respectively. The estimated survival times of the low and high UA/A ratio groups were 27.7 days (95% confidence interval [CI], 26.2–29.3) and 23.9 days (95% Cl, 22.0–25.9), respectively.
We found a direct correlation between 30-day mortality and UA/A ratio at initial presentation in AKI patients regardless of age, comorbidities, and clinical and laboratory findings, including albuminuria.
Hypoalbuminemia and hyperuricemia have been associated with acute kidney injury and mortality separately.
We found that the relationship between 30-day mortality and uric acid albumin ratio at the time of the first presentation in patients with acute kidney injury was independent of age, comorbidities, and other clinical and laboratory findings, including albuminuria.
In addition to being the main determinant of intravascular oncotic pressure, albumin is a key molecule in the body’s defense mechanisms playing roles in anti-inflammation, anti-apoptosis, and protection from oxidative stress [
Uric acid is a notable waste product of purine metabolism and is mostly cleared by the kidneys with a small percentage removed directly by the intestines [
Acute kidney injury (AKI) is diagnosed via a rapid increase in serum creatinine level, decrease in urine output, or combination of both, and is characterized by a rapid deterioration in kidney function [
This study was conducted in accordance with the Declaration of Helsinki after obtaining the necessary ethics committee permission (2019/514/148/4). It was planned for in-hospital implementation. It was designed as a prospective observational study on patients with AKI by obtaining written informed consent. All patients who applied to the emergency service over the age of 18 between 1 May and 30 September 2019 who developed AKI and were seen at the internal medicine clinic for follow-up and treatment were included in the study. Patients who did not meet AKI criteria were excluded from the study. No assistance was received from any funding agency or sponsor in this study.
According to the Kidney Disease Improving Global Outcomes (KDIGO) guide, AKI was diagnosed by meeting at least one of the following criteria: ≥0.3 mg/dL increase in serum creatinine level within 48 hours, greater than or equal to 1.5 times increase in serum creatinine level in the last 7 days compared to baseline, and urine output of <0.5 mL/kg/hr in 6 hours [
AKI staging is also done as follows according to the KDIGO guide [
The socio-demographic characteristics, comorbidities, and clinical findings of all patients participating in the study were recorded in study specific report forms. In addition, length of hospital stay was recorded from the emergency admission to the discharge from the hospital. Within 30 days after the initial form completion, the status of the patients was checked through the national death notification system and was recorded in report forms. Serum creatinine (if available, also base level serum creatinine levels in the last 3 months), urea, albumin, sodium, potassium, chloride, calcium, phosphorus, uric acid, hemoglobin levels, power of hydrogen, and bicarbonate levels (the last two via venous blood gas) at the time of emergency service stay were recorded. In addition to the proteinuria, hematuria, or pyuria observed in a standard urinalysis measured with a urine dipstick; albumin level was also measured by turbidimetric method in spot urine (mg/L). Blood creatinine and spot urine creatinine (mg/dL) concentration were measured by Beckman Coulter AU5832 device (Beckman Coulter, Brea, CA, USA) with kinetic color test (Jaffe method). Afterwards, spot urine albumin and creatinine levels were proportioned to each other, and urine albumin creatinine ratio was calculated in mg/g value. Hypoalbuminemia was defined as plasma albumin level of less than 3.5 g/dL; hyperuricemia was defined as plasma uric acid level higher than 7 mg/dL.
The hospital admission dates, length of hospital stay, release from the clinic dates, discharge status (as are, with cure, transfer to intensive care unit [ICU], and exit), and dates of transfer to ICU for all the patients were recorded in the same manner. The hospital stay (internal medicine ward±ICU) starting on the date of admission to the emergency department was recorded with the 30-day follow-up performed after. The in-hospital mortality status of the patients was checked from the hospital data systems; and the 30-day mortality status was checked from the national death notification system. All findings were recorded in the case report forms.
After evaluating the distributions via the Kolmogorov-Smirnov test, variables with normal distribution were expressed as mean±standard deviation, and those without normal distribution were expressed as median (interquartile range). Categorical variables were reported as numbers and percentages. Patient characteristics among each group were compared using the chi-squared test or Fisher exact test for categorical variables and the MannWhitney U-test or student t-test for continuous variables. To determine the best UA/A cut off level in the 30-day mortality estimate, diagnostic odds ratio (DOR; (+) likelihood ratios/(-) likelihood ratio, Youden index (J; % sensitivity+% specificity-100), and area under the receiver operating characteristic curve (AUROC; [sensitivity+specificity] / 2) were used. The 30-day survival analysis was performed utilizing Kaplan-Meier curves. Cox-regression analysis was utilized to identify the UA/A for mortality. P-values of <0.05 were considered statistically significant. All statistical analyses were performed using IBM SPSS Statistics ver. 22 (IBM Corp., Armonk, NY, USA).
A total of 171 patients, with an average age of 69.2±13.0 years, 45.6% of whom were females, were seen at the internal medicine clinic in the 4 months observed, were included in the study. Among them, 62.6% of the patients were hypoalbuminemic, and 61.7% were hyperuricemic. Regarding comorbidities, 63.7% of patients had hypertension, 51.5% had chronic kidney disease (CKD), 35.7% had diabetes mellitus (DM), 31% had malignancy, 24.6% had coronary artery disease, 19.3% had congestive heart failure, 14% had chronic obstructive pulmonary disease, 9.4% of them had a history of stroke, 5.8% had Alzheimer disease, and 3.5% had liver cirrhosis. The median Charlson comorbidity score of all patients was 5 (range, 0 to 14).
It was observed that 25.1% of patients (43/171) died within the 30-day period, of which 22.8% (39/171) expired during the hospital stay.
UA/A ratio was significantly higher in the non-survivors group compared to the survivor group (mean of 3.25±1.5 and 2.52±1, respectively; P=0.001). ROC analysis was performed to determine the best UA/A ratio cut-off point in mortality estimation with the best cut-off level determined at 2.36 mg/g with 52% specificity and 77% sensitivity (AUROC, 0.644; DOR, 3.59; J, 28.8).
As seen in
By univariate cox regression analysis: age, presence of malignancy, proteinuria, Charlson comorbidity score, respiratory rate, corrected calcium, albumin, uric acid levels, and UA/A ratio were all related to 30-day mortality. In multivariate analysis, it was found that 30-day mortality was associated with UA/A ratio even when controlling for all the other above mentioned variables (hazard ratio, 1.39; 95% Cl, 1.02 to 1.91; P=0.04) (
After determining the UA/A ratio level most associated with mortality, the patients were divided into two groups labeled as low and high UA/A ratio (>2.36 and <2.36, respectively), and their clinical and biochemical properties were compared as seen in
This study demonstrated the relationship between UA/A ratio on initial admission in patients with AKI and the 30-day mortality rate. It has been shown that the relationship between mortality and UA/A ratio exists independent of age, malignancy, Charlson comorbidity score, respiratory rate, and presence of ascites in multivariate models. Also, in this study, the best UA/A ratio cut-off level associated with 30-day mortality was determined as 2.36 mg/g in patients with AKI (sensitivity, 77%; specificity, 52%; AUROC, 0.644; DOR, 3.59; J, 28.8).
In a study conducted by Yeter et al. [
In patients with DM, it was detected that serum uric acid levels correlated with urinary albumin excretion [
A positive relationship has been reported between hyperuricemia and cardiovascular disease, but no study has yet proven the definitive role of serum uric acid in the development of cardiovascular disease. In addition, although the antioxidant effect of uric acid has recently been shown to inhibit DNA damage, no epidemiological studies have documented reduced cancer risk among people with hyperuricemia. Tomita et al. [
Previous studies have shown that both low albumin and high uric acid levels are associated with development of AKI and increased mortality. By combining these two strongly related situations seen in the literature, we have created a stronger predictor of mortality. In short-term mortality estimations, we determined the best sensitivity and specificity rates, AUROC, DOR and J as well as the best cut-off level. When we divide our patients into two groups according to this cut-of level, it was also emphasized that high UA/A ratio was significantly associated with high mortality rate and low survival time.
Despite the strengths of our study, there were some limitations. First of all, patient treatments during hospitalization and medical conditions that developed after hospitalization, which were thought to have an effect on mortality, were not included in the study. This was because our study was designed based on only initial data recorded in the hospital admission. Secondly, our study cannot be generalized for other disease groups since it was performed in the AKI patients group only. In spite of this, it can provide a template for the studies to be carried out with different disease groups and for wider populations.
In summary, our study population consisted of renal, prerenal and postrenal AKI patients whose disease was caused by many different pathophysiological mechanisms such as hepatorenal syndrome due to liver cirrhosis, chemotherapy toxicity, contrast nephropathy, dehydration, and bladder cancer. We aimed to investigate the relationship between mortality rates and the synergism of both hyperuricemia and hypoalbuminemia independent of these etiological factors. Indeed, regardless of age, Charlson comorbidity score, and clinical parameters, we found the above mentioned to be associated with an increased risk of short-term mortality. We thus present a result-oriented practical approximate without etiological differences.
No potential conflict of interest relevant to this article was reported.
Kaplan-Meier survival graphics by uric acid albumin ratio (UA/A) ratio.
Comparison of the clinical features of the patients according to their 30-day mortality
Survivors (n=128) | Non-survivors (n=43) | P-value | |
---|---|---|---|
Demographics and comorbidities | |||
Age (yr) | 67.8 (13.7) | 73.3 (9.9) | 0.018 |
Sex, female | 58 (45.3) | 20 (46.5) | 0.891 |
Diabetes mellitus | 46 (35.9) | 15 (34.9) | 0.901 |
Hypertension | 80 (62.5) | 29 (67.4) | 0.560 |
Chronic kidney disease | 67 (52.3) | 21 (48.8) | 0.691 |
Liver cirrhosis | 3 (2.3) | 3 (7.0) | 0.168 |
Malignancy | 34 (26.6) | 19 (44.2) | 0.031 |
Charlson comorbidity score | 5.0 (2.4) | 6.3 (2.7) | 0.002 |
Clinical and laboratory findings | |||
SBP (mmHg) | 123.6 (27.8) | 116.0 (29.0) | 0.134 |
DBP (mmHg) | 72.6 (14.5) | 67.6 (14.0) | 0.056 |
Pulse rate (bpm/min) | 86.3 (16.6) | 91.2 (21.0) | 0.130 |
Respiratory rate (rpm/min) | 14.9 (4.1) | 19.1 (6.4) | 0.001 |
Oxygen saturation (%) | 95.4 (2.5) | 94.3 (4.2) | 0.257 |
Ascites (%) | 13 (11.6) | 12 (30.0) | 0.007 |
Pretibial edema (%) | 44 (34.4) | 21 (48.8) | 0.025 |
Glucose (mg/dL) | 143.0 (84.8) | 149.8 (121.0) | 0.691 |
Basal creatinine (mg/dL) | 1.5 (0.9) | 1.6 (1.2) | 0.780 |
Creatinine (mg/dL) | 4.2 (1.9) | 3.9 (2.9) | 0.450 |
Urea (mg/dL) | 162.2 (73.5) | 171.5 (70.7) | 0.469 |
Total protein (mg/dL) | 62.7 (8.7) | 61.9 (14.2) | 0.714 |
Albumin (mg/dL) | 33.2 (6.6) | 29.7 (6.4) | 0.003 |
Uric acid (mg/dL) | 8.0 (2.7) | 9.3 (4.0) | 0.016 |
UA/A ratio (mg/g) | 2.52 (1.0) | 3.25 (1.5) | 0.001 |
UACR (mg/g) | 899.8 (777.7) | 772.4 (1,480.1) | 0.772 |
Sodium (mEq/L) | 133.9 (6.4) | 133.0 (9.4) | 0.566 |
Potassium (mEq/L) | 4.9 (1.1) | 5.0 (1.1) | 0.068 |
Chlorine (mEq/L) | 102.1 (7.5) | 100.4 (8.6) | 0.237 |
Calcium (mg/dL) | 8.5 (1.2) | 9.0 (2.3) | 0.244 |
Corrected calcium (mg/dL) | 9.1 (1.2) | 9.8 (2.2) | 0.050 |
Phosphorusm (mg/dL) | 4.4 (1.5) | 4.7 (1.7) | 0.335 |
Hemoglobin (g/dL) | 10.0 (2.4) | 9.6 (2.4) | 0.334 |
Power of hydrogen | 7.32 (0.1) | 7.34 (0.1) | 0.045 |
Bicarbonate (mEq/L) | 18.6 (4.9) | 19.8 (5.1) | 0.174 |
Proteinuria (dipstick, %) | 75 (58.6) | 16 (65.1) | 0.030 |
Hematuria (dipstick, %) | 77 (60.1) | 12 (44.1) | 0.082 |
Leucocyturia (dipstick, %) | 43 (33.6) | 21 (25.6) | 0.691 |
Hypoalbuminemia (%) | 74 (57.8) | 33 (76.7) | 0.019 |
Hyperuricemia (%) | 68 (57.1) | 32 (74.4) | 0.033 |
High UA/A ratio (%) | 58 (48.7) | 33 (76.7) | 0.002 |
Length of hospital stay | |||
In internal medicine ward without ICU | 13.7 (11.4) | 6.8 (5.8) | < 0.001 |
In internal medicine ward with ICU | 14.3 (12.1) | 11.5 (8.4) | 0.097 |
30-Day survival time | 30.0 (0) | 13.5 (8.9) | < 0.001 |
Values are presented as median (interquartile range) or number (%).
SBP, systolic blood pressure; DBP, diastolic blood pressure; UA/A, uric acid albumin ratio; UACR, urine albumin creatinine ratio; ICU, intensive care unit.
Cox Proportional Hazard Analysis for 30-day mortality
Univariate analysis |
Multivariate analysis |
|||
---|---|---|---|---|
P-value | HR (95% Cl) | P-value | HR (95% Cl) | |
Age | 0.029 | 1.03 (1.00-1.06) | 0.747 | 0.99 (0.95-1.03) |
Malignancy | 0.029 | 1.96 (1.07-3.58) | 0.373 | 1.44 (0.65-3.19) |
Carlson comorbidity score | 0.001 | 1.22 (1.08-1.38) | 0.169 | 1.14 (0.95-1.37) |
Respiratory rate | 0.000 | 1.11 (1.06-1.16) | 0.033 | 1.07 (1.01-1.14) |
Ascides | 0.012 | 2.39 (1.22-4.71) | 0.279 | 1.72 (0.64-4.59) |
Pretibial edema | 0.084 | 1.73 (0.93-3.22) | ||
Corrected calcium | 0.060 | 1.19 (1.04-1.35) | ||
Albumin | 0.003 | 0.93 (0.89-0.98) | ||
Uric acid | 0.019 | 1.11 (1.02-1.21) | ||
UA/A ratio | 0.000 | 1.45 (1.18-1.80) | 0.029 | 1.39 (1.02-1.91) |
Power of Hydrogen | 0.058 | 37.9 (0.89-1625) | ||
Proteinuria dipstick | 0.010 | 0.57 (0.37-0.87) | ||
Hypoalbuminemia | 0.033 | 2.16 (1.06-4.37) | ||
Hyperuricemia | 0.055 | 1.95 (0.98-3.88) | ||
High UA/A ratio | 0.003 | 2.94 (1.45-5.96) |
HR, hazard ratio; CI, confidential interval; UA/A, uric acid albumin ratio.
Comparative characteristics of patients according to UA/A ratio
UA/A ratio <2.36 (n=71) | UA/A ratio >2.36 (n=91) | P-value | |
---|---|---|---|
Demographics and comorbidities | |||
Age (yr) | 68.5 (12.2) | 70.1 (13.3) | 0.434 |
Sex, female | 32 (45.1) | 44 (48.4) | 0.678 |
Diabetes mellitus | 22 (31.0) | 37 (40.7) | 0.204 |
Duration of diabetes (yr) | 11.3 (6.0) | 15.5 (8.1) | 0.087 |
Hypertension | 44 (62.0) | 58 (63.7) | 0.818 |
Duration of hypertension (yr) | 11.2 (8.7) | 14.0 (9.2) | 0.164 |
Chronic kidney disease | 42 (59.2) | 41 (45.1) | 0.075 |
Duration of chronic kidney disease (yr) | 5.5 (8.3) | 5.9 (5.2) | 0.837 |
Liver cirrhosis | 0 (0.0) | 6 (6.6) | 0.029 |
Duration of cirrhosis (yr) | 1.0 (1.2) | ||
Oncological malignancy | 19 (26.8) | 32 (35.2) | 0.253 |
Duration of oncological malignancy (yr) | 3.6 (4.5) | 3.7 (5.0) | 0.982 |
Charlson comorbidity score | 4.8 (2.5) | 5.8 (2.4) | 0.007 |
Clinical and laboratory findings | |||
Systolic blood pressure (mmHg) | 126.9 (29.3) | 117.9 (27.2) | 0.049 |
Diastolic blood pressure (mmHg) | 74.5 (13.3) | 69.3 (15.3) | 0.026 |
Pulse rate (bpm/min) | 85.8 (18.2) | 88.5 (18.3) | 0.361 |
Oxygen saturation (%) | 95.2 (2.6) | 94.1 (4.2) | 0.174 |
Body temperature (°C) | 36.8 (0.6) | 36.8 (0.6) | 0.896 |
Respiratory rate (rpm/min) | 15.2 (5.2) | 16.7 (5.2) | 0.092 |
Ascites (%) | 5 (8.1) | 20 (23.8) | 0.013 |
Pretibial edema (%) | 19 (28.4) | 44 (51.2) | 0.008 |
Glucose (mg/dL) | 137.0 (55.9) | 152.2 (121.6) | 0.337 |
Basal creatinine (mg/dL) | 1.5 (0.9) | 1.5 (1.0) | 0.858 |
Creatinine (mg/dL) | 4.2 (2.0) | 4.0 (2.3) | 0.615 |
Urea (mg/dL) | 148.5 (64.0) | 171.5 (71.8) | 0.035 |
Total protein (mg/dL) | 63.7 (11.0) | 61.5 (10.1) | 0.270 |
Albumin (mg/dL) | 34.8 (6.8) | 30.2 (6.2) | 0.000 |
Uric acid (mg/dL) | 5.8 (1.6) | 10.3 (2,7) | 0.000 |
UACR (mg/g) | 1,155.3 (1,166.2) | 602.5 (624.0) | 0.155 |
Sodium (mEq/L) | 135.0 (6.6) | 132.8 (7.3) | 0.048 |
Potassium (mEq/L) | 4.8 (1.1) | 5.0 (1.0) | 0.358 |
Chlorine (mEq/L) | 103.2 (7.4) | 100.4 (7.8) | 0.021 |
Calcium (mg/dL) | 8.5 (1.1) | 8.8 (1.9) | 0.217 |
Corrected calcium (mg/dL) | 8.9 (1.1) | 9.6 (1.8) | 0.005 |
Phosphorusm (mg/dL) | 4.2 (1.5) | 4.6 (1.6) | 0.103 |
Hemoglobin (g/dL) | 9.6 (2.3) | 10.1 (2.4) | 0.231 |
Power of hydrogen | 7.3 (0.1) | 7.3 (0.1) | 0.420 |
Bicarbonate (mEq/L) | 18.7 (4.6) | 19.3 (5.1) | 0.388 |
Outcomes | |||
Length of hospital stay |
12.3 (10.3) | 11.6 (11.1) | 0.704 |
Length of hospital stay |
12.9 (10.8) | 14.2 (11.9) | 0.476 |
30-Day survival time | 27.7 (6.6) | 24.0 (9.6) | 0.006 |
In-hospital mortality rate | 10 (14.1) | 29 (31.9) | 0.009 |
30-Day mortality rate | 10 (14.1) | 33 (36.3) | 0.002 |
Values are presented as median (interquartile range) or number (%).
UA/A, uric acid albumin ratio; UACR, urine albumin creatinine ratio.
Only in internal medicine ward without ICU.
Total time internal medicine ward with intensive care unit.